The 12mg dose produced more than twice the rate of the 9mg dose, suggesting a clear relationship between glucagon receptor activation intensity and this side effect
Tirzepatide produces greater average weight loss (20.2% vs 13.7% body weight at 15 months), which affects cost-effectiveness calculations
Empowering Patients: Education, Decision-Making, and Prognosis Understanding uterine fibroid symptoms, diagnostic results, and treatment options is crucial for patient empowerment
A revolutionary, safe, and non-habit-forming medication class for lasting weight loss, currently the most effective on the market
Key Points: -Both trials met all primary and key secondary endpoints, including weight loss and cardiometabolic improvements -The 12 mg dose performed as well as or better than 36 mg, suggesting a strong efficacy tolerability balance -With four of five Phase 3 trials successful, Lilly plans to file for Type 2 diabetes approval in 2026 Orforglipron could expand access to GLP-1 therapy, especially for patients preferring oral formulations or struggling with injectable adherence, a significant step toward more personalized diabetes management
